# A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

> **NCT06313983** · PHASE3 · RECRUITING · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 339 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Hemay022+AI
- **DRUG:** Lapatinib+Capecitabine

## Key facts

- **NCT ID:** NCT06313983
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-08
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 339 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313983, "A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06313983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*